Physicians

Department / Division
Medicine / Medicine-Infectious Diseases

Address
DUMC 3360
Durham, NC 27710

Appointment Telephone
919-681-6261

Fax Telephone
919-684-8902

Training

• MD, George Washington University School of Medicine and Health Sciences (Washington, DC), 1979

Residency

• Internal Medicine, Letterman Army Medical Center (California), 1979-1982

Fellowship

• Medical Science, Walter Reed Army Institute of Research (Washington, DC), 1984-1985
• Infectious Diseases, Walter Reed Army Medical Center (Washington, DC), 1985-1988

Clinical Interests
HIV infection including acute HIV infection and its treatment, general infectious diseases

Research Interests
My research interests are primarily focussed on two areas.  First, I am the PI on a consortium of investigators studying primary HIV infection (PHI) with an emphasis on improving recognition and diagnosis of PHI, on elucidating virologic and immunologic events occurring in different compartments during PHI, and on studying host-virus interactions during very early HIV infection.  My second focus involves determining the factors associated with prolonged immunologic responses to incompletely suppressive antiretroviral therapy.  I also continue to be involved in phase 1-3 studies of new antiretroviral agents with support from the pharmaceutical industry.

Industry Relationships and Collaborations (What's this?)

This physician (or a member of their immediate family) has a working relationship (i.e. consulting, research, and/or educational services) with the companies listed below. These relations have been reported to the health system leadership and, when appropriate, management plans are in place to address potential conflicts.

• Abbott Laboratories
• Bristol-Myers Squibb
• Gilead Sciences, Inc.
• GlaxoSmithKline
• Merck Sharpe & Dohme (Merck & Co, USA)
• Tibotec

Representative Publications
Sufka SA, Ferrari G, Gryszowka VE, Wrin T, Fiscus SA, Tomaras GD, Staats HF, Patel DD, Sempowski GD, Hellmann NS, Weinhold KJ, Hicks CB. Prolonged CD4+ cell/virus load discordance during treatment with protease inhibitor-based highly active antiretroviral therapy: immune response and viral control.  J Infect Dis.  2003 Apr 1;187(7):1027-37. (2003) Abstract

Weintrob AC, Giner J, Menezes P, Patrick E, Benjamin DK Jr, Lennox J, Pilcher CD, Eron JJ, Hicks CB. Infrequent diagnosis of primary human immunodeficiency virus infection: missed opportunities in acute care settings.  Arch Intern Med.  2003 Sep 22;163(17):2097-100. (2003) Abstract

Bohjanen PR, Johnson MD, Szczech LA, Wray DW, Petros WP, Miller CR, Hicks CB. Steady-state pharmacokinetics of Lamivudine in human immunodeficiency virus-infected patients with end-stage renal disease receiving chronic dialysis. Antimicrob Agents Chemother. 2002 Aug;46(8):2387-92. (2002) Abstract

4. Murphy RL, Brun S, Hicks C, et al. ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naïve adults with HIV-1 infection: 48-week results. AIDS (Fast Track) 2001;15:F1-F9. (2001)